SHPH | Shuttle Pharmaceuticals Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.3501 - 0.4090
52 Week Range	0.3310 - 4.71
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	50,945
Average Volume	135,059
Shares Outstanding	6,257,693
Market Cap	2,434,243
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2022-08-31

Valuation
Profitability
Growth
Health
P/E Ratio	-0.12
Forward P/E Ratio	N/A
EPS	-3.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	SHPH

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

SHPH's peers: AKAN, AQST, AYTU, BFRI, BHC, CPHI, CPIX, DERM, DRRX, COSM, EVOK, KALA, KMDA, OPTN, ORGO, PTPI, SBFM, SCYX, SIGA, SNOA, SXTC, TEVA, LFCR, CTLT, LSDI, TLRY, MNK, ALIM, ATNX, AGRX

*Chart delayed

Analyzing fundamentals for SHPH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see SHPH Fundamentals page.

Watching at SHPH technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on SHPH Technicals page.